Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Business Officer | January 03, 2025 | January 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date January 03, 2025 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,878 |
Reported balance
After 2025-01-03 transaction · row 1
1 source rowRow 1 · 2025-01-03 · Sale · Disposed 6,502 · Balance 59,878 F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1 and January 3, 2025, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1 and January 3, 2025, and does not represent a volitional trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,502 | $12.18 | $79,194.36 |
DisclosureSEC source: 0000950170-25-003014 · ownership.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,878 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1 and January 3, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 42,421 | $0.00 Strike: $32.66 | $0.00 |
DisclosureSEC source: 0000950170-24-025903 · ownership.xml · derivative · entry 2 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,421 Underlying: Common Stock · 42,421 shares Expires 2034-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 29,393 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025903 · ownership.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,380 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,877 | $29.46 | $114,216.42 |
DisclosureSEC source: 0000950170-24-002507 · ownership.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,987 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1 and January 3, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:31 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock option (right to buy) · Derivative | 33,287 | $0.00 Strike: $40.75 | $0.00 |
DisclosureSEC source: 0001209191-23-015817 · doc4.xml · derivative · entry 2 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,287 Underlying: Common Stock · 33,287 shares Expires 2033-02-28 F2 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:31 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 23,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015817 · doc4.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,864 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,812 | $37.21 | $67,424.52 |
DisclosureSEC source: 0001209191-23-002421 · doc4.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,306 F1 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 3, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $118.99 | $0.00 |
DisclosureSEC source: 0001209191-22-001651 · doc4.xml · derivative · entry 2 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2022 with respect to 25,000 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 25% vesting on December 20, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 19,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001651 · doc4.xml · nonDerivative · entry 1 Hicks Derek · CIK 0001901282 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,118 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.